Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

•Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affect...

Full description

Saved in:
Bibliographic Details
Published inEuropean neuropsychopharmacology Vol. 41; pp. 81 - 91
Main Authors Hutten, Nadia R.P.W., Mason, Natasha L., Dolder, Patrick C., Theunissen, Eef L., Holze, Friederike, Liechti, Matthias E., Feilding, Amanda, Ramaekers, Johannes G., Kuypers, Kim P.C.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.12.2020
Subjects
Online AccessGet full text
ISSN0924-977X
1873-7862
1873-7862
DOI10.1016/j.euroneuro.2020.10.002

Cover

Abstract •Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affects are present following 20 mcg of LSD. There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
AbstractList There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
•Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affects are present following 20 mcg of LSD. There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
Author Mason, Natasha L.
Dolder, Patrick C.
Kuypers, Kim P.C.
Hutten, Nadia R.P.W.
Feilding, Amanda
Theunissen, Eef L.
Liechti, Matthias E.
Ramaekers, Johannes G.
Holze, Friederike
Author_xml – sequence: 1
  givenname: Nadia R.P.W.
  surname: Hutten
  fullname: Hutten, Nadia R.P.W.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
– sequence: 2
  givenname: Natasha L.
  surname: Mason
  fullname: Mason, Natasha L.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
– sequence: 3
  givenname: Patrick C.
  surname: Dolder
  fullname: Dolder, Patrick C.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
– sequence: 4
  givenname: Eef L.
  surname: Theunissen
  fullname: Theunissen, Eef L.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
– sequence: 5
  givenname: Friederike
  surname: Holze
  fullname: Holze, Friederike
  organization: Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
– sequence: 6
  givenname: Matthias E.
  surname: Liechti
  fullname: Liechti, Matthias E.
  organization: Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
– sequence: 7
  givenname: Amanda
  surname: Feilding
  fullname: Feilding, Amanda
  organization: The Beckley Foundation, Beckley Park, Oxford, UK
– sequence: 8
  givenname: Johannes G.
  surname: Ramaekers
  fullname: Ramaekers, Johannes G.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
– sequence: 9
  givenname: Kim P.C.
  surname: Kuypers
  fullname: Kuypers, Kim P.C.
  organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33082016$$D View this record in MEDLINE/PubMed
BookMark eNqNks9vFCEcxYmpsdvqv6AcvcwWhmF-mBizqVpN1nhQE2-EhS8tKwtbYNrMxb9ddrf20NNeIHm894APnKETHzwg9IaSOSW0vVjPYYxFKsO8JvVOnRNSP0Mz2nes6vq2PkEzMtRNNXTd71N0ltKaEMoZG16gU8ZIX5eeGfr7LQSNpddYhWtvsw0eS5MhYqk31tuUo9yLwWAX7vHyx0esQ4KErcc3IF2-mfBdcKPPADG9wwu8dVLBKpRCn2NwDvQ-UYExoDI21mvrr3HKo55eoudGugSvHuZz9Ovzp5-XX6rl96uvl4tlpZquzZWUnFHdsU73ph863tBh1fCWcC4Jg6bVPZWEGsoGYLwzmshWEYDeGAqc64ado_7QO_qtnO6lc2Ib7UbGSVAidkjFWjwiFTuku4WCtETfHqLbGG5HSFlsbFLgnPQQxiTqhteF8UD6Yn39YB1XG9CPW_zHXQzvDwYVQ0oRjFA27_kWzNYdcZbuSf74WywOSSiU7yxEkZQFr0DbWF5F6GCP6PjwpEO58kWUdH9gOqrhH4y828U
CitedBy_id crossref_primary_10_1038_s41398_024_02900_4
crossref_primary_10_1089_psymed_2024_0005
crossref_primary_10_1177_02698811231225609
crossref_primary_10_1007_s40263_023_01008_5
crossref_primary_10_1016_j_psychres_2024_115886
crossref_primary_10_1177_20494637221114962
crossref_primary_10_2139_ssrn_3910688
crossref_primary_10_7554_eLife_66920
crossref_primary_10_1080_02791072_2022_2080616
crossref_primary_10_1177_02698811211050556
crossref_primary_10_1038_s41380_024_02743_x
crossref_primary_10_15406_jpcpy_2023_14_00738
crossref_primary_10_1016_j_evopsy_2021_03_013
crossref_primary_10_3389_fpsyt_2023_1088896
crossref_primary_10_3390_ijms24021329
crossref_primary_10_1111_adb_13143
crossref_primary_10_1007_s00213_022_06106_8
crossref_primary_10_1016_j_neuropharm_2025_110334
crossref_primary_10_1124_pharmrev_120_000056
crossref_primary_10_1080_02791072_2024_2304554
crossref_primary_10_1177_02698811231190865
crossref_primary_10_1016_j_jns_2022_120332
crossref_primary_10_1016_j_bpsc_2024_01_002
crossref_primary_10_1017_S0033291722002963
crossref_primary_10_1007_s00213_021_05991_9
crossref_primary_10_1038_s41598_023_34938_7
crossref_primary_10_1016_j_socscimed_2024_116702
crossref_primary_10_1111_soc4_12959
crossref_primary_10_1186_s40345_022_00265_5
crossref_primary_10_1016_j_nsa_2022_101012
crossref_primary_10_7554_eLife_62878
crossref_primary_10_1176_appi_ajp_20230890
crossref_primary_10_1371_journal_pone_0307491
crossref_primary_10_1186_s13063_021_05243_3
crossref_primary_10_1177_13634615221129115
crossref_primary_10_1556_2054_2021_00157
crossref_primary_10_1177_02698811241254831
crossref_primary_10_1007_s00213_021_05857_0
crossref_primary_10_1016_j_expneurol_2022_114148
crossref_primary_10_1093_nc_niae038
crossref_primary_10_1016_j_neuropharm_2025_110402
crossref_primary_10_1001_jamapsychiatry_2025_0044
crossref_primary_10_3389_fpsyt_2024_1217102
crossref_primary_10_1038_s41386_022_01479_y
crossref_primary_10_1016_j_biopha_2023_115775
crossref_primary_10_1038_s41597_022_01822_4
crossref_primary_10_1038_s41386_023_01588_2
crossref_primary_10_1080_02791072_2022_2125467
crossref_primary_10_1002_advs_202413786
crossref_primary_10_1038_s41386_024_01809_2
crossref_primary_10_1016_j_neubiorev_2022_104706
crossref_primary_10_1080_02791072_2022_2047842
crossref_primary_10_1177_02698811241301216
crossref_primary_10_1007_s00213_021_05978_6
crossref_primary_10_1038_s41398_022_02039_0
crossref_primary_10_1055_a_1486_7386
crossref_primary_10_3389_fnins_2022_832375
crossref_primary_10_1177_02698811231200019
crossref_primary_10_1177_02698811241303599
crossref_primary_10_1038_s41380_022_01832_z
crossref_primary_10_1016_j_nlm_2021_107467
crossref_primary_10_3390_brainsci14030248
crossref_primary_10_1007_s00213_022_06170_0
crossref_primary_10_1038_s41598_024_65391_9
crossref_primary_10_1186_s40814_024_01449_9
crossref_primary_10_1016_j_biopsych_2022_10_021
crossref_primary_10_1007_s40263_023_01044_1
crossref_primary_10_1016_j_biopsych_2023_03_013
crossref_primary_10_1038_s41398_024_03013_8
Cites_doi 10.1001/jama.2013.281053
10.1590/S1984-82502010000400011
10.1016/j.biopsych.2014.11.015
10.1021/acsptsci.0c00099
10.1177/0269881120940937
10.1093/ijnp/pyz029
10.1017/S0012162201001384
10.1097/JCP.0000000000000941
10.1177/0269881114568040
10.1016/S0893-133X(02)00343-3
10.1016/j.edurev.2010.12.001
10.1016/j.peh.2019.01.001
10.1111/bcp.13918
10.1002/cpt.2057
10.1001/archneurpsyc.1958.02340020088016
10.1097/NMD.0000000000000113
10.2174/138161208786549344
10.1371/journal.pone.0211023
10.1111/j.1530-0277.2001.tb02248.x
10.1016/j.biopsych.2019.05.019
10.1038/nrn2884
10.1007/s00213-018-5119-x
10.4088/JCP.v67n1110
10.1523/JNEUROSCI.1088-12.2012
10.1371/journal.pone.0012412
10.1007/s00213-016-4453-0
10.1177/2045125316638008
10.1038/s41386-019-0569-3
10.1177/0269881114555249
10.1016/j.drugalcdep.2012.11.010
10.3758/BF03203313
10.1016/j.euroneuro.2019.06.003
10.1017/S0033291715002901
10.1177/1455072517753339
10.1016/j.neuropsychologia.2007.02.019
10.1186/s12954-019-0308-4
10.3758/BF03200977
10.1007/BF00413239
10.1038/sj.npp.1300637
10.1097/00004583-199912000-00006
10.1038/npp.2016.82
10.3389/fnhum.2016.00269
ContentType Journal Article
Copyright 2020
Copyright © 2020. Published by Elsevier B.V.
Copyright_xml – notice: 2020
– notice: Copyright © 2020. Published by Elsevier B.V.
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
ADTOC
UNPAY
DOI 10.1016/j.euroneuro.2020.10.002
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-7862
EndPage 91
ExternalDocumentID 10.1016/j.euroneuro.2020.10.002
33082016
10_1016_j_euroneuro_2020_10_002
S0924977X20309111
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AADFP
AAEDT
AAEDW
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABFRF
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ACXNI
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRLJ
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDW
HMK
HMO
HMQ
HMT
HVGLF
HZ~
IHE
J1W
KOM
LX8
M29
M2V
M34
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OGGZJ
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPT
SSB
SSH
SSN
SSP
SSY
SSZ
T5K
UNMZH
WUQ
XPP
Z5R
~G-
6I.
AACTN
AADPK
AAFTH
AAIAV
AATCM
ABLVK
ABYKQ
AFCTW
AFKWA
AFYLN
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
AAYXX
ACLOT
CITATION
~HD
NPM
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c476t-aa531d737d8f8975419b456055a03e46d81a01f139e357fd0a6c0ee8ff1e55d43
IEDL.DBID .~1
ISSN 0924-977X
1873-7862
IngestDate Tue Aug 19 21:37:12 EDT 2025
Sun Sep 28 11:10:13 EDT 2025
Wed Feb 19 02:29:50 EST 2025
Thu Apr 24 23:01:08 EDT 2025
Wed Oct 01 03:11:39 EDT 2025
Fri Feb 23 02:46:13 EST 2024
Tue Aug 26 16:32:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Psychedelic experience
Mood
LSD
Microdose
Healthy
Attention
Language English
License This is an open access article under the CC BY license.
Copyright © 2020. Published by Elsevier B.V.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c476t-aa531d737d8f8975419b456055a03e46d81a01f139e357fd0a6c0ee8ff1e55d43
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0924977X20309111
PMID 33082016
PQID 2452977908
PQPubID 23479
PageCount 11
ParticipantIDs unpaywall_primary_10_1016_j_euroneuro_2020_10_002
proquest_miscellaneous_2452977908
pubmed_primary_33082016
crossref_citationtrail_10_1016_j_euroneuro_2020_10_002
crossref_primary_10_1016_j_euroneuro_2020_10_002
elsevier_sciencedirect_doi_10_1016_j_euroneuro_2020_10_002
elsevier_clinicalkey_doi_10_1016_j_euroneuro_2020_10_002
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2020
2020-12-00
20201201
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: December 2020
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle European neuropsychopharmacology
PublicationTitleAlternate Eur Neuropsychopharmacol
PublicationYear 2020
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Dinges, Powell (bib0009) 1985; 17
Lea, Amada, Jungaberle (bib0037) 2019
Anderson, Petranker, Christopher, Rosenbaum, Weissman, Dinh-Williams, Hapke (bib0001) 2019; 16
DIMS, 2019. Jaarbericht 2018. (Accessed 18 May 2020). Retrieved from Utrecht
Hupli, Berning, Zhuparris, Fadiman (bib0025) 2019; 6
Moreno, Wiegand, Taitano, Delgado (bib0044) 2006; 67
Vollenweider, Kometer (bib0056) 2010; 11
Gasser, Kirchner, Passie (bib0015) 2015; 29
Johnstad (bib0032) 2018; 35
Holze, Duthaler, Vizeli, Müller, Borgwardt, Liechti (bib0022) 2019; 85
Glatter, R., 2015. LSD microdosing: the new job enhancer in Silicon Valley. (Accessed 30 November 2018). Retrieved from
Brown, Prescott (bib0004) 2014
(bib0059) 2013; 310
Bershad, Schepers, Bremmer, Lee, de Wit (bib0003) 2019; 86
Winstock, A.R., Barrett, M.J., Ferris, J.A., & Maier, L.J., 2017. Global drug survey (GDS) 2017. Global overview and highlights. (Accessed 24 June 2019). Retrieved from
Johnson, Robertson, Kelly, Silk, Barry, Dáibhis, Gallagher (bib0031) 2007; 45
Gasser, Holstein, Michel, Doblin, Yazar-Klosinski, Passie, Brenneisen (bib0014) 2014; 202
Ramaekers, Hutten, Mason, Dolder, Theunissen, Holze, Kuypers (bib0048) 2020
Liechti, Dolder, Schmid (bib0038) 2017; 234
Winsberg, Comings (bib0057) 1999; 38
Thethirdwave, 2018. Microdosing. (Accessed 30 November 2018). Retrieved from
Holdstock, de Wit (bib0021) 2001; 25
Studerus, Gamma, Vollenweider (bib0052) 2010; 5
Majić, Schmidt, Gallinat (bib0040) 2015; 29
van der Meulen, Wijnberg, Hollander, van de Hoofdakker (bib0045) 1980
Bershad, Preller, Lee, Keedy, Wren-Jarvis, Bremmer, de Wit (bib0002) 2019; 5
Ilgin, Senol, Gucuyener, Gokcora, Atavci, Sener (bib0029) 2001; 43
Jaeger (bib0030) 2018; 38
Kuypers, Livia, Erritzoe, Knudsen, Nichols, Nichols, Nutt (bib0035) 2019
.
Carhart-Harris, Kaelen, Bolstridge, Williams, Williams, Underwood, Nutt (bib0005) 2016; 46
Hutten, Mason, Dolder, Kuypers (bib0026) 2019; 22
Polito, Stevenson (bib0047) 2019; 14
Szigeti (bib0053) 2020
De Wit, Enggasser, Richards (bib0006) 2002; 27
Family, Maillet, Williams, Krediet, Carhart-Harris, Williams, Raz (bib0013) 2019
Santos, G., Osorio, Crippa, Riba, Zuardi, Hallak (bib0011) 2016; 6
Mirsky, Kornetsky (bib0043) 1964; 5
Hutten, Mason, Dolder, Theunissen, Holze, Liechti, Kuypers (bib0027) 2020
McLeod, Griffiths, Bigelow, Yingling (bib0042) 1982; 14
Kuypers, K.P.C., Hutten, N.R.P.W., Mason, N.L., Dolder, P.C., Theunissen, E.L., Holze, F., Ramaekers, J.G., 2020. A low dose of LSD has minimal to no effects on creative processes and empathy but increases self-rated content in written stories. (Submitted).
Richardson (bib0049) 2011; 6
Sahakian, B., d'Angelo, C., & Savulich, G., 2018. `Microdosing' LSD is not just a Silicon Valley trend - it is spreading to other workplaces. (Accessed 5 May 2019). Retrieved from
Holze, Vizeli, Müller, Ley, Duerig, Varghese, Liechti (bib0024) 2020; 45
Marinho, Leite (bib0041) 2010; 46
Yanakieva, Polychroni, Family, Williams, Luke, Terhune (bib0060) 2019; 236
Hutten, Steenbergen, Colzato, Hommel, Theunissen, Ramaekers, Kuypers (bib0028) 2019; 29
Holze, Liechti, Hutten, Mason, Dolder, Duthaler, Kuypers (bib0023) 2020
Nour, Evans, Nutt, Carhart-Harris (bib0046) 2016; 10
Fadiman (bib0012) 2011
Schmid, Enzler, Gasser, Grouzmann, Preller, Vollenweider, Liechti (bib0051) 2015; 78
Greiner, Burch, Edelberg (bib0017) 1958; 79
Lott, Kim, Cook Jr, de Wit (bib0039) 2005; 30
Landolt (bib0036) 2008; 14
Dolder, Schmid, Müller, Borgwardt, Liechti (bib0010) 2016; 41
de Wit, Watson, Harsay, Cohen, van de Vijver, Ridderinkhof (bib0007) 2012; 32
Hallock, Dean, Knecht, Spencer, Taverna (bib0018) 2013; 130
10.1016/j.euroneuro.2020.10.002_bib0034
Anderson (10.1016/j.euroneuro.2020.10.002_bib0001) 2019; 16
Holze (10.1016/j.euroneuro.2020.10.002_bib0022) 2019; 85
Gasser (10.1016/j.euroneuro.2020.10.002_bib0015) 2015; 29
Ramaekers (10.1016/j.euroneuro.2020.10.002_bib0048) 2020
Winsberg (10.1016/j.euroneuro.2020.10.002_bib0057) 1999; 38
Hutten (10.1016/j.euroneuro.2020.10.002_bib0028) 2019; 29
Landolt (10.1016/j.euroneuro.2020.10.002_bib0036) 2008; 14
Dolder (10.1016/j.euroneuro.2020.10.002_bib0010) 2016; 41
Greiner (10.1016/j.euroneuro.2020.10.002_bib0017) 1958; 79
Santos (10.1016/j.euroneuro.2020.10.002_bib0011) 2016; 6
Ilgin (10.1016/j.euroneuro.2020.10.002_bib0029) 2001; 43
Carhart-Harris (10.1016/j.euroneuro.2020.10.002_bib0005) 2016; 46
Jaeger (10.1016/j.euroneuro.2020.10.002_bib0030) 2018; 38
Nour (10.1016/j.euroneuro.2020.10.002_bib0046) 2016; 10
Hallock (10.1016/j.euroneuro.2020.10.002_bib0018) 2013; 130
Szigeti (10.1016/j.euroneuro.2020.10.002_bib0053) 2020
Moreno (10.1016/j.euroneuro.2020.10.002_bib0044) 2006; 67
Bershad (10.1016/j.euroneuro.2020.10.002_bib0003) 2019; 86
Mirsky (10.1016/j.euroneuro.2020.10.002_bib0043) 1964; 5
Hutten (10.1016/j.euroneuro.2020.10.002_bib0026) 2019; 22
Johnstad (10.1016/j.euroneuro.2020.10.002_bib0032) 2018; 35
de Wit (10.1016/j.euroneuro.2020.10.002_bib0007) 2012; 32
De Wit (10.1016/j.euroneuro.2020.10.002_bib0006) 2002; 27
Hutten (10.1016/j.euroneuro.2020.10.002_bib0027) 2020
10.1016/j.euroneuro.2020.10.002_bib0054
Schmid (10.1016/j.euroneuro.2020.10.002_bib0051) 2015; 78
10.1016/j.euroneuro.2020.10.002_bib0016
Hupli (10.1016/j.euroneuro.2020.10.002_bib0025) 2019; 6
10.1016/j.euroneuro.2020.10.002_bib0058
Holze (10.1016/j.euroneuro.2020.10.002_bib0023) 2020
Marinho (10.1016/j.euroneuro.2020.10.002_bib0041) 2010; 46
Yanakieva (10.1016/j.euroneuro.2020.10.002_bib0060) 2019; 236
Gasser (10.1016/j.euroneuro.2020.10.002_bib0014) 2014; 202
Kuypers (10.1016/j.euroneuro.2020.10.002_bib0035) 2019
Majić (10.1016/j.euroneuro.2020.10.002_bib0040) 2015; 29
Lea (10.1016/j.euroneuro.2020.10.002_bib0037) 2019
Richardson (10.1016/j.euroneuro.2020.10.002_bib0049) 2011; 6
Johnson (10.1016/j.euroneuro.2020.10.002_bib0031) 2007; 45
Polito (10.1016/j.euroneuro.2020.10.002_bib0047) 2019; 14
Brown (10.1016/j.euroneuro.2020.10.002_bib0004) 2014
10.1016/j.euroneuro.2020.10.002_bib0050
Holze (10.1016/j.euroneuro.2020.10.002_bib0024) 2020; 45
Fadiman (10.1016/j.euroneuro.2020.10.002_bib0012) 2011
Vollenweider (10.1016/j.euroneuro.2020.10.002_bib0056) 2010; 11
Bershad (10.1016/j.euroneuro.2020.10.002_bib0002) 2019; 5
10.1016/j.euroneuro.2020.10.002_bib0008
Family (10.1016/j.euroneuro.2020.10.002_bib0013) 2019
(10.1016/j.euroneuro.2020.10.002_bib0059) 2013; 310
Dinges (10.1016/j.euroneuro.2020.10.002_bib0009) 1985; 17
Studerus (10.1016/j.euroneuro.2020.10.002_bib0052) 2010; 5
Lott (10.1016/j.euroneuro.2020.10.002_bib0039) 2005; 30
Liechti (10.1016/j.euroneuro.2020.10.002_bib0038) 2017; 234
Holdstock (10.1016/j.euroneuro.2020.10.002_bib0021) 2001; 25
McLeod (10.1016/j.euroneuro.2020.10.002_bib0042) 1982; 14
van der Meulen (10.1016/j.euroneuro.2020.10.002_bib0045) 1980
References_xml – volume: 234
  start-page: 1499
  year: 2017
  end-page: 1510
  ident: bib0038
  article-title: Alterations of consciousness and mystical-type experiences after acute LSD in humans
  publication-title: Psychopharmacol. Berl.
– volume: 16
  start-page: 43
  year: 2019
  ident: bib0001
  article-title: Psychedelic microdosing benefits and challenges: an empirical codebook
  publication-title: Harm Reduct. J.
– volume: 22
  start-page: 426
  year: 2019
  end-page: 434
  ident: bib0026
  article-title: Motives and side-effects of microdosing with psychedelics among users
  publication-title: Int. J. Neuropsychopharmacol.
– volume: 310
  start-page: 2191
  year: 2013
  end-page: 2194
  ident: bib0059
  article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects
  publication-title: JAMA
– volume: 17
  start-page: 652
  year: 1985
  end-page: 655
  ident: bib0009
  article-title: Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations
  publication-title: Behav. Res. Methods Instrum. Comput.
– year: 2020
  ident: bib0048
  article-title: A low dose of lysergic acid diethylamide (LSD) decreases pain perception in healthy volunteers
  publication-title: J. Psychopharmacol.
– volume: 78
  start-page: 544
  year: 2015
  end-page: 553
  ident: bib0051
  article-title: Acute effects of lysergic acid diethylamide in healthy subjects
  publication-title: Biol. Psychiatry
– volume: 46
  start-page: 1379
  year: 2016
  end-page: 1390
  ident: bib0005
  article-title: The paradoxical psychological effects of lysergic acid diethylamide (LSD)
  publication-title: Psychol. Med.
– volume: 46
  start-page: 695
  year: 2010
  end-page: 703
  ident: bib0041
  article-title: Quantification of LSD in illicit samples by high performance liquid chromatography
  publication-title: Braz. J. Pharm. Sci.
– volume: 130
  start-page: 245
  year: 2013
  end-page: 248
  ident: bib0018
  article-title: A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students
  publication-title: Drug Alcohol Depend.
– reference: Thethirdwave, 2018. Microdosing. (Accessed 30 November 2018). Retrieved from
– volume: 41
  start-page: 2638
  year: 2016
  ident: bib0010
  article-title: LSD acutely impairs fear recognition and enhances emotional empathy and sociality
  publication-title: Neuropsychopharmacology
– start-page: 1
  year: 2019
  end-page: 19
  ident: bib0035
  article-title: Microdosing psychedelics: more questions than answers? An overview and suggestions for future research
  publication-title: J. Psychopharmacol.
– volume: 14
  year: 2019
  ident: bib0047
  article-title: A systematic study of microdosing psychedelics
  publication-title: PLoS ONE
– volume: 79
  start-page: 208
  year: 1958
  end-page: 210
  ident: bib0017
  article-title: Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum
  publication-title: AMA Arch. Neurol. Psychiatry
– volume: 5
  start-page: e12412
  year: 2010
  ident: bib0052
  article-title: Psychometric evaluation of the altered states of consciousness rating scale (OAV)
  publication-title: PLoS ONE
– year: 2020
  ident: bib0053
  article-title: Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology [abstract]
  publication-title: Proceedings of the Interdisciplinary Conference on Psychedelic Research
– volume: 27
  start-page: 813
  year: 2002
  end-page: 825
  ident: bib0006
  article-title: Acute administration of d-amphetamine decreases impulsivity in healthy volunteers
  publication-title: Neuropsychopharmacology
– volume: 67
  start-page: 1735
  year: 2006
  end-page: 1740
  ident: bib0044
  article-title: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
  publication-title: J. Clin. Psychiatry
– volume: 29
  start-page: 813
  year: 2019
  end-page: 824
  ident: bib0028
  article-title: Cocaine enhances figural, but impairs verbal ‘flexible'divergent thinking
  publication-title: Eur. Neuropsychopharmacol.
– year: 2020
  ident: bib0023
  article-title: Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants
  publication-title: Clin Pharmacol & Ther
– volume: 38
  start-page: 513
  year: 2018
  end-page: 519
  ident: bib0030
  article-title: Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing
  publication-title: J. Clin. Psychopharmacol.
– volume: 45
  start-page: 2234
  year: 2007
  end-page: 2245
  ident: bib0031
  article-title: Dissociation in performance of children with ADHD and high-functioning autism on a task of sustained attention
  publication-title: Neuropsychologia
– volume: 86
  start-page: 792
  year: 2019
  end-page: 800
  ident: bib0003
  article-title: Acute subjective and behavioral effects of microdoses of LSD in healthy human volunteers
  publication-title: Biol. Psychiatry
– volume: 43
  start-page: 755
  year: 2001
  end-page: 760
  ident: bib0029
  article-title: Is increased D2 receptor availability associated with response to stimulant medication in ADHD
  publication-title: Dev. Med. Child Neurol.
– volume: 14
  start-page: 3396
  year: 2008
  end-page: 3407
  ident: bib0036
  article-title: Genotype-dependent differences in sleep, vigilance, and response to stimulants
  publication-title: Curr. Pharm. Des.
– volume: 6
  start-page: 129
  year: 2019
  end-page: 138
  ident: bib0025
  article-title: Descriptive assemblage of psychedelic microdosing: netnographic study of Youtube™ videos and on-going research projects
  publication-title: Perform. Enhanc. Health
– year: 1980
  ident: bib0045
  article-title: Measurements of sleep quality
  publication-title: Proceedings of the European Sleep Conference
– start-page: 1
  year: 2019
  end-page: 12
  ident: bib0037
  article-title: Psychedelic microdosing: a subreddit analysis
  publication-title: J. Psychoact. Drugs
– reference: DIMS, 2019. Jaarbericht 2018. (Accessed 18 May 2020). Retrieved from Utrecht:
– volume: 6
  start-page: 135
  year: 2011
  end-page: 147
  ident: bib0049
  article-title: Eta squared and partial eta squared as measures of effect size in educational research
  publication-title: Educ. Res. Rev.
– volume: 32
  start-page: 12066
  year: 2012
  end-page: 12075
  ident: bib0007
  article-title: Corticostriatal connectivity underlies individual differences in the balance between habitual and goal-directed action control
  publication-title: J. Neurosci.
– volume: 45
  start-page: 462
  year: 2020
  end-page: 471
  ident: bib0024
  article-title: Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
  publication-title: Neuropsychopharmacology
– volume: 5
  start-page: 461
  year: 2019
  end-page: 467
  ident: bib0002
  article-title: Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity
  publication-title: Biol. Psychiatry Cogn. Neurosci. Neuroimaging
– volume: 5
  start-page: 161
  year: 1964
  end-page: 177
  ident: bib0043
  article-title: On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests
  publication-title: Psychopharmacologia
– volume: 30
  start-page: 602
  year: 2005
  ident: bib0039
  article-title: Dopamine transporter gene associated with diminished subjective response to amphetamine
  publication-title: Neuropsychopharmacology
– volume: 6
  start-page: 193
  year: 2016
  end-page: 213
  ident: bib0011
  article-title: Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
  publication-title: Ther. Adv. Psychopharmacol.
– volume: 35
  start-page: 39
  year: 2018
  end-page: 51
  ident: bib0032
  article-title: Powerful substances in tiny amounts: an interview study of psychedelic microdosing
  publication-title: Nord. Stud. Alcohol Drugs
– reference: Kuypers, K.P.C., Hutten, N.R.P.W., Mason, N.L., Dolder, P.C., Theunissen, E.L., Holze, F., Ramaekers, J.G., 2020. A low dose of LSD has minimal to no effects on creative processes and empathy but increases self-rated content in written stories. (Submitted).
– volume: 29
  start-page: 241
  year: 2015
  end-page: 253
  ident: bib0040
  article-title: Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
  publication-title: J. Psychopharmacol.
– volume: 29
  start-page: 57
  year: 2015
  end-page: 68
  ident: bib0015
  article-title: LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects
  publication-title: J. Psychopharmacol.
– reference: Winstock, A.R., Barrett, M.J., Ferris, J.A., & Maier, L.J., 2017. Global drug survey (GDS) 2017. Global overview and highlights. (Accessed 24 June 2019). Retrieved from
– volume: 236
  start-page: 1159
  year: 2019
  end-page: 1170
  ident: bib0060
  article-title: The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
  publication-title: Psychopharmacol. Berl.
– start-page: 1
  year: 2019
  end-page: 13
  ident: bib0013
  article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
  publication-title: Psychopharmacol. Berl.
– volume: 14
  start-page: 463
  year: 1982
  end-page: 466
  ident: bib0042
  article-title: An automated version of the digit symbol substitution test (DSST)
  publication-title: Behav. Res. Methods Instrum.
– year: 2011
  ident: bib0012
  article-title: The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys
– year: 2020
  ident: bib0027
  article-title: Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
  publication-title: ACS Pharmacol. Transl. Sci.
– year: 2014
  ident: bib0004
  article-title: Applied Mixed Models in Medicine
– volume: 10
  start-page: 269
  year: 2016
  ident: bib0046
  article-title: Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)
  publication-title: Front. Hum. Neurosci.
– reference: .
– reference: Glatter, R., 2015. LSD microdosing: the new job enhancer in Silicon Valley. (Accessed 30 November 2018). Retrieved from
– volume: 38
  start-page: 1474
  year: 1999
  end-page: 1477
  ident: bib0057
  article-title: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response
  publication-title: J. Am. Acad. Child Adolesc. Psychiatry
– volume: 25
  start-page: 540
  year: 2001
  end-page: 548
  ident: bib0021
  article-title: Individual differences in responses to ethanol and d-amphetamine: a within-subject study
  publication-title: Alcohol. Clin. Exp. Res.
– volume: 85
  start-page: 1474
  year: 2019
  end-page: 1483
  ident: bib0022
  article-title: Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
  publication-title: Br. J. Clin. Pharmacol
– volume: 11
  start-page: 642
  year: 2010
  ident: bib0056
  article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
  publication-title: Nat. Rev. Neurosci.
– volume: 202
  start-page: 513
  year: 2014
  ident: bib0014
  article-title: Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
  publication-title: J. Nerv. Ment. Dis.
– reference: Sahakian, B., d'Angelo, C., & Savulich, G., 2018. `Microdosing' LSD is not just a Silicon Valley trend - it is spreading to other workplaces. (Accessed 5 May 2019). Retrieved from
– volume: 310
  start-page: 2191
  issue: 20
  year: 2013
  ident: 10.1016/j.euroneuro.2020.10.002_bib0059
  article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects
  publication-title: JAMA
  doi: 10.1001/jama.2013.281053
– volume: 46
  start-page: 695
  year: 2010
  ident: 10.1016/j.euroneuro.2020.10.002_bib0041
  article-title: Quantification of LSD in illicit samples by high performance liquid chromatography
  publication-title: Braz. J. Pharm. Sci.
  doi: 10.1590/S1984-82502010000400011
– volume: 78
  start-page: 544
  issue: 8
  year: 2015
  ident: 10.1016/j.euroneuro.2020.10.002_bib0051
  article-title: Acute effects of lysergic acid diethylamide in healthy subjects
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2014.11.015
– year: 2020
  ident: 10.1016/j.euroneuro.2020.10.002_bib0027
  article-title: Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
  publication-title: ACS Pharmacol. Transl. Sci.
  doi: 10.1021/acsptsci.0c00099
– ident: 10.1016/j.euroneuro.2020.10.002_bib0034
– year: 2020
  ident: 10.1016/j.euroneuro.2020.10.002_bib0048
  article-title: A low dose of lysergic acid diethylamide (LSD) decreases pain perception in healthy volunteers
  publication-title: J. Psychopharmacol.
  doi: 10.1177/0269881120940937
– volume: 22
  start-page: 426
  issue: 7
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0026
  article-title: Motives and side-effects of microdosing with psychedelics among users
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyz029
– volume: 43
  start-page: 755
  issue: 11
  year: 2001
  ident: 10.1016/j.euroneuro.2020.10.002_bib0029
  article-title: Is increased D2 receptor availability associated with response to stimulant medication in ADHD
  publication-title: Dev. Med. Child Neurol.
  doi: 10.1017/S0012162201001384
– volume: 5
  start-page: 461
  issue: 4
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0002
  article-title: Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity
  publication-title: Biol. Psychiatry Cogn. Neurosci. Neuroimaging
– volume: 38
  start-page: 513
  issue: 5
  year: 2018
  ident: 10.1016/j.euroneuro.2020.10.002_bib0030
  article-title: Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/JCP.0000000000000941
– volume: 29
  start-page: 241
  issue: 3
  year: 2015
  ident: 10.1016/j.euroneuro.2020.10.002_bib0040
  article-title: Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
  publication-title: J. Psychopharmacol.
  doi: 10.1177/0269881114568040
– year: 2014
  ident: 10.1016/j.euroneuro.2020.10.002_bib0004
– year: 2020
  ident: 10.1016/j.euroneuro.2020.10.002_bib0053
  article-title: Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology [abstract]
– volume: 27
  start-page: 813
  issue: 5
  year: 2002
  ident: 10.1016/j.euroneuro.2020.10.002_bib0006
  article-title: Acute administration of d-amphetamine decreases impulsivity in healthy volunteers
  publication-title: Neuropsychopharmacology
  doi: 10.1016/S0893-133X(02)00343-3
– volume: 6
  start-page: 135
  issue: 2
  year: 2011
  ident: 10.1016/j.euroneuro.2020.10.002_bib0049
  article-title: Eta squared and partial eta squared as measures of effect size in educational research
  publication-title: Educ. Res. Rev.
  doi: 10.1016/j.edurev.2010.12.001
– ident: 10.1016/j.euroneuro.2020.10.002_bib0008
– volume: 6
  start-page: 129
  issue: 3
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0025
  article-title: Descriptive assemblage of psychedelic microdosing: netnographic study of Youtube™ videos and on-going research projects
  publication-title: Perform. Enhanc. Health
  doi: 10.1016/j.peh.2019.01.001
– volume: 85
  start-page: 1474
  issue: 7
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0022
  article-title: Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
  publication-title: Br. J. Clin. Pharmacol
  doi: 10.1111/bcp.13918
– ident: 10.1016/j.euroneuro.2020.10.002_bib0054
– start-page: 1
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0013
  article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
  publication-title: Psychopharmacol. Berl.
– year: 2020
  ident: 10.1016/j.euroneuro.2020.10.002_bib0023
  article-title: Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants
  publication-title: Clin Pharmacol & Ther
  doi: 10.1002/cpt.2057
– volume: 79
  start-page: 208
  issue: 2
  year: 1958
  ident: 10.1016/j.euroneuro.2020.10.002_bib0017
  article-title: Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum
  publication-title: AMA Arch. Neurol. Psychiatry
  doi: 10.1001/archneurpsyc.1958.02340020088016
– ident: 10.1016/j.euroneuro.2020.10.002_bib0058
– ident: 10.1016/j.euroneuro.2020.10.002_bib0050
– volume: 202
  start-page: 513
  issue: 7
  year: 2014
  ident: 10.1016/j.euroneuro.2020.10.002_bib0014
  article-title: Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
  publication-title: J. Nerv. Ment. Dis.
  doi: 10.1097/NMD.0000000000000113
– start-page: 1
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0035
  article-title: Microdosing psychedelics: more questions than answers? An overview and suggestions for future research
  publication-title: J. Psychopharmacol.
– volume: 14
  start-page: 3396
  issue: 32
  year: 2008
  ident: 10.1016/j.euroneuro.2020.10.002_bib0036
  article-title: Genotype-dependent differences in sleep, vigilance, and response to stimulants
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/138161208786549344
– volume: 14
  issue: 2
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0047
  article-title: A systematic study of microdosing psychedelics
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0211023
– volume: 25
  start-page: 540
  issue: 4
  year: 2001
  ident: 10.1016/j.euroneuro.2020.10.002_bib0021
  article-title: Individual differences in responses to ethanol and d-amphetamine: a within-subject study
  publication-title: Alcohol. Clin. Exp. Res.
  doi: 10.1111/j.1530-0277.2001.tb02248.x
– volume: 86
  start-page: 792
  issue: 10
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0003
  article-title: Acute subjective and behavioral effects of microdoses of LSD in healthy human volunteers
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2019.05.019
– volume: 11
  start-page: 642
  issue: 9
  year: 2010
  ident: 10.1016/j.euroneuro.2020.10.002_bib0056
  article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
  publication-title: Nat. Rev. Neurosci.
  doi: 10.1038/nrn2884
– volume: 236
  start-page: 1159
  issue: 4
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0060
  article-title: The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
  publication-title: Psychopharmacol. Berl.
  doi: 10.1007/s00213-018-5119-x
– volume: 67
  start-page: 1735
  issue: 11
  year: 2006
  ident: 10.1016/j.euroneuro.2020.10.002_bib0044
  article-title: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.v67n1110
– volume: 32
  start-page: 12066
  issue: 35
  year: 2012
  ident: 10.1016/j.euroneuro.2020.10.002_bib0007
  article-title: Corticostriatal connectivity underlies individual differences in the balance between habitual and goal-directed action control
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.1088-12.2012
– volume: 5
  start-page: e12412
  issue: 8
  year: 2010
  ident: 10.1016/j.euroneuro.2020.10.002_bib0052
  article-title: Psychometric evaluation of the altered states of consciousness rating scale (OAV)
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0012412
– ident: 10.1016/j.euroneuro.2020.10.002_bib0016
– volume: 234
  start-page: 1499
  issue: 9–10
  year: 2017
  ident: 10.1016/j.euroneuro.2020.10.002_bib0038
  article-title: Alterations of consciousness and mystical-type experiences after acute LSD in humans
  publication-title: Psychopharmacol. Berl.
  doi: 10.1007/s00213-016-4453-0
– volume: 6
  start-page: 193
  issue: 3
  year: 2016
  ident: 10.1016/j.euroneuro.2020.10.002_bib0011
  article-title: Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
  publication-title: Ther. Adv. Psychopharmacol.
  doi: 10.1177/2045125316638008
– start-page: 1
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0037
  article-title: Psychedelic microdosing: a subreddit analysis
  publication-title: J. Psychoact. Drugs
– volume: 45
  start-page: 462
  issue: 3
  year: 2020
  ident: 10.1016/j.euroneuro.2020.10.002_bib0024
  article-title: Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
  publication-title: Neuropsychopharmacology
  doi: 10.1038/s41386-019-0569-3
– volume: 29
  start-page: 57
  issue: 1
  year: 2015
  ident: 10.1016/j.euroneuro.2020.10.002_bib0015
  article-title: LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects
  publication-title: J. Psychopharmacol.
  doi: 10.1177/0269881114555249
– volume: 130
  start-page: 245
  issue: 1–3
  year: 2013
  ident: 10.1016/j.euroneuro.2020.10.002_bib0018
  article-title: A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students
  publication-title: Drug Alcohol Depend.
  doi: 10.1016/j.drugalcdep.2012.11.010
– volume: 14
  start-page: 463
  issue: 5
  year: 1982
  ident: 10.1016/j.euroneuro.2020.10.002_bib0042
  article-title: An automated version of the digit symbol substitution test (DSST)
  publication-title: Behav. Res. Methods Instrum.
  doi: 10.3758/BF03203313
– volume: 29
  start-page: 813
  issue: 7
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0028
  article-title: Cocaine enhances figural, but impairs verbal ‘flexible'divergent thinking
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2019.06.003
– volume: 46
  start-page: 1379
  issue: 7
  year: 2016
  ident: 10.1016/j.euroneuro.2020.10.002_bib0005
  article-title: The paradoxical psychological effects of lysergic acid diethylamide (LSD)
  publication-title: Psychol. Med.
  doi: 10.1017/S0033291715002901
– volume: 35
  start-page: 39
  issue: 1
  year: 2018
  ident: 10.1016/j.euroneuro.2020.10.002_bib0032
  article-title: Powerful substances in tiny amounts: an interview study of psychedelic microdosing
  publication-title: Nord. Stud. Alcohol Drugs
  doi: 10.1177/1455072517753339
– volume: 45
  start-page: 2234
  issue: 10
  year: 2007
  ident: 10.1016/j.euroneuro.2020.10.002_bib0031
  article-title: Dissociation in performance of children with ADHD and high-functioning autism on a task of sustained attention
  publication-title: Neuropsychologia
  doi: 10.1016/j.neuropsychologia.2007.02.019
– volume: 16
  start-page: 43
  issue: 1
  year: 2019
  ident: 10.1016/j.euroneuro.2020.10.002_bib0001
  article-title: Psychedelic microdosing benefits and challenges: an empirical codebook
  publication-title: Harm Reduct. J.
  doi: 10.1186/s12954-019-0308-4
– volume: 17
  start-page: 652
  issue: 6
  year: 1985
  ident: 10.1016/j.euroneuro.2020.10.002_bib0009
  article-title: Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations
  publication-title: Behav. Res. Methods Instrum. Comput.
  doi: 10.3758/BF03200977
– volume: 5
  start-page: 161
  issue: 3
  year: 1964
  ident: 10.1016/j.euroneuro.2020.10.002_bib0043
  article-title: On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests
  publication-title: Psychopharmacologia
  doi: 10.1007/BF00413239
– volume: 30
  start-page: 602
  issue: 3
  year: 2005
  ident: 10.1016/j.euroneuro.2020.10.002_bib0039
  article-title: Dopamine transporter gene associated with diminished subjective response to amphetamine
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300637
– year: 2011
  ident: 10.1016/j.euroneuro.2020.10.002_bib0012
– year: 1980
  ident: 10.1016/j.euroneuro.2020.10.002_bib0045
  article-title: Measurements of sleep quality
– volume: 38
  start-page: 1474
  issue: 12
  year: 1999
  ident: 10.1016/j.euroneuro.2020.10.002_bib0057
  article-title: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response
  publication-title: J. Am. Acad. Child Adolesc. Psychiatry
  doi: 10.1097/00004583-199912000-00006
– volume: 41
  start-page: 2638
  issue: 11
  year: 2016
  ident: 10.1016/j.euroneuro.2020.10.002_bib0010
  article-title: LSD acutely impairs fear recognition and enhances emotional empathy and sociality
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2016.82
– volume: 10
  start-page: 269
  year: 2016
  ident: 10.1016/j.euroneuro.2020.10.002_bib0046
  article-title: Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)
  publication-title: Front. Hum. Neurosci.
  doi: 10.3389/fnhum.2016.00269
SSID ssj0015339
Score 2.560557
Snippet •Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood...
There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific...
SourceID unpaywall
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 81
SubjectTerms Attention
Healthy
LSD
Microdose
Mood
Psychedelic experience
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7C5lB6SJ9JtyRlCiGnaGNbsuXNbUkbQmnCQrOwORnZI4e2xg7dXcL2kN9eSX6k2wd5XG3GWKOR9In55huAXRmQ8DVJprjOmVBhwIYeJxYTqSyQUgvXi-D0LDqZiE_TcLoGB20tzEr-3vGwrEaF03Y0l7nAPh048cj1yGaUerA-ORuPLpyiXiCYQTNTe8WKJWfSgPUVRtc_v_S_8-hvvPkUnizKK7W8VkXx2xl0_AzG7d_X1JPvg8U8HWQ__xB2fMDwnsNGg0dxVAfQC1jT5UvYG9eC1st9PL-tz5rt4x6Ob6Wul6_g5rSqCFVJ2NCQqhJd13FUK6K8WOVYVNf4-csHpGqmZ_i1xLoEc4l2gzTTa3DoIY7QkcTSChsOfaHJWbCaeIIux15eopPFfQ2T44_nRyes6ejAMiGjOVPKLHmSXFKcx0MZCn-YGgTnhaHyuBYRxb7y_NygUs1DmZOnoszTOs5zX4chCb4JvdK46w2gzHighuSngTRXKJ6qNMoyMicyBSI3qKQPUTuvSdbInduuG0XS8tq-JZ3vE-t7-8L4vg9eZ3hVK37cbRK3gZO0Ba1mC07MbN9tetiZNpinxjL3M37fRmlidgWb6lGlrhazxOXTrZRk3IetOny7wXDuYF_UB7-L5_uO9O0jbLahN_-x0DsGvM3Td82C_QWbW0Th
  priority: 102
  providerName: Unpaywall
Title Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0924977X20309111
https://dx.doi.org/10.1016/j.euroneuro.2020.10.002
https://www.ncbi.nlm.nih.gov/pubmed/33082016
https://www.proquest.com/docview/2452977908
https://doi.org/10.1016/j.euroneuro.2020.10.002
UnpaywallVersion publishedVersion
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1873-7862
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015339
  issn: 1873-7862
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1873-7862
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015339
  issn: 1873-7862
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1873-7862
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015339
  issn: 1873-7862
  databaseCode: AIKHN
  dateStart: 19950301
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection 2025
  customDbUrl:
  eissn: 1873-7862
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015339
  issn: 1873-7862
  databaseCode: ACRLP
  dateStart: 19950301
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1873-7862
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015339
  issn: 1873-7862
  databaseCode: AKRWK
  dateStart: 19901101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9swFD6U7mHbw9i92aWcwehTtdiSbDl9C9lKtrUhrA1kT0a25JFh7LAklLz0t08X213YoIU9GV8OWD5HR5-s73wCeC-o4qFWgkimC8JlRMkgYIokSsmcCqG524vgfBKPZ_zLPJrvwaithbG0yib3-5zusnVzpd98zf5ysehfBHbqIMSc2lWC0NX3WvUvE9Mfrjuah4UzXm-PcmKf3uF4Wf0LpxtpJorUXu3-r_xjhPobgT6E-5tqKbdXsiz_GJVOH8OjBk7i0L_xE9jT1VM4mno96u0xXt6UV62O8QinN0rV22dwfV7XCmWlsGER1RW6TcNR7mjqYl1gWV_h2cVHVPVKr3BRoa-g3KLNb8Y7Bkae4BAdxyursaHAl1o5C-J5I-iWyKsf6FRtn8Ps9NPlaEyaDRlIzkW8JlKaHqsEEyopkoGIeDjIDAALokgGTPNYJaEMwsKASs0iUahAxnmgdVIUoY4ixdkL2K_MBz8AFDmjcqDCjAozA2KZzOI8V2ZAVZQXBlT0IG6dkOaNWrndNKNMW1raz7TzXmq9Z28Y7_Ug6AyXXrDjdpOk9XLa1qOaDJqaQeV205POdCds72b8rg2p1HRqu1IjK11vVqlbDrdKkEkPXvpY6xrDmENtcQ_CLvju2tJX__O6r-GBPfNcnjewv_610W8NIltnh67LHcK94ejb2dQeP38dT8xxNpkOv_8GTvQ8ow
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9K-tDtYXTfafdxg9GnitiWbDl9C-1Kuiah0BTyZmRLLhnGDktCyUv_9unDdhs2aGGvFgeS7nT3k-_uJ4DvPJDMV5ITQVVOmAgD0veoJLGUIgs4V8y-RTCeRMMb9nMWznbgtOmFMWWVte93Pt166_pLr97N3mI-71175urA-SwwWQLf9PfuslD75A7sDi4uh5M2maARjaPcCxgxAltlXoYCw1JH6rtiYL62v1j-EaT-BqEvYW9dLsTmThTFo8B0vg-vakSJAzfp17CjyjdwdOUoqTfHOH3osFoe4xFePZBVb97C_biqJIpSYl1IVJVo3w1HsUWri1WORXWHo-szlNVSLXFeomui3KBxcVpBGkme4ABtmVdaYV0FXyhpJYgrHUGbJS9v0RLbvoOb8x_T0yGp32QgGePRigihD63klMs4j_tc73c_1RjMC0PhUcUiGfvC83ONKxUNeS49EWWeUnGe-yoMJaPvoVPqDf8IyDMaiL7004DrSxBNRRplmdQxVQYs17iiC1GjhCSrCcvNuxlF0lSm_Upa7SVGe2ZAa68LXiu4cJwdT4vEjZaTpiVVO9FEx5WnRU9a0S3LfZ7wt8akEn2uTbJGlKpaLxObETdkkHEXPjhbaxdDqQVuURf81vieu9KD_5nuV9gbTsejZHQxuTyEF2bElfZ8gs7q91p91gBtlX6pD-AfIQ48CQ
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7C5lB6SJ9JtyRlCiGnaGNbsuXNbUkbQmnCQrOwORnZI4e2xg7dXcL2kN9eSX6k2wd5XG3GWKOR9In55huAXRmQ8DVJprjOmVBhwIYeJxYTqSyQUgvXi-D0LDqZiE_TcLoGB20tzEr-3vGwrEaF03Y0l7nAPh048cj1yGaUerA-ORuPLpyiXiCYQTNTe8WKJWfSgPUVRtc_v_S_8-hvvPkUnizKK7W8VkXx2xl0_AzG7d_X1JPvg8U8HWQ__xB2fMDwnsNGg0dxVAfQC1jT5UvYG9eC1st9PL-tz5rt4x6Ob6Wul6_g5rSqCFVJ2NCQqhJd13FUK6K8WOVYVNf4-csHpGqmZ_i1xLoEc4l2gzTTa3DoIY7QkcTSChsOfaHJWbCaeIIux15eopPFfQ2T44_nRyes6ejAMiGjOVPKLHmSXFKcx0MZCn-YGgTnhaHyuBYRxb7y_NygUs1DmZOnoszTOs5zX4chCb4JvdK46w2gzHighuSngTRXKJ6qNMoyMicyBSI3qKQPUTuvSdbInduuG0XS8tq-JZ3vE-t7-8L4vg9eZ3hVK37cbRK3gZO0Ba1mC07MbN9tetiZNpinxjL3M37fRmlidgWb6lGlrhazxOXTrZRk3IetOny7wXDuYF_UB7-L5_uO9O0jbLahN_-x0DsGvM3Td82C_QWbW0Th
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mood+and+cognition+after+administration+of+low+LSD+doses+in+healthy+volunteers%3A+A+placebo+controlled+dose-effect+finding+study&rft.jtitle=European+neuropsychopharmacology&rft.au=Hutten%2C+Nadia+R.P.W.&rft.au=Mason%2C+Natasha+L.&rft.au=Dolder%2C+Patrick+C.&rft.au=Theunissen%2C+Eef+L.&rft.date=2020-12-01&rft.pub=Elsevier+B.V&rft.issn=0924-977X&rft.volume=41&rft.spage=81&rft.epage=91&rft_id=info:doi/10.1016%2Fj.euroneuro.2020.10.002&rft.externalDocID=S0924977X20309111
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0924-977X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0924-977X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0924-977X&client=summon